Unicycive Therapeutics

UNCY

Market cap $142M

6.27 USD

-0.34

5.14%

At close Updated Jan 15, 4:00 PM EST

Pre-market

After hours

6.34

+0.07

1.12%

1 day

-5.14%

5 days

2.28%

1 month

6.63%

3 months

30.62%

6 months

35.71%

Year to date

8.1%

1 year

-6.42%

5 years

-89.28%

10 years

-89.28%

About: Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.

Employees: 22

Healthcare Biotechnology